- Home
- PCVX vs CELH Comparison
PCVX vs CELH Comparison
Compare PCVX & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | CELH |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.9B |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PCVX | CELH |
|---|---|---|
| Price | $60.91 | $28.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 24 |
| Target Price | ★ $117.30 | $41.62 |
| AVG Volume (30 Days) | 3.4M | ★ 5.0M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $1,318,014,000.00 |
| Revenue This Year | N/A | $26.10 |
| Revenue Next Year | N/A | $8.53 |
| P/E Ratio | ★ N/A | $60.35 |
| Revenue Growth | N/A | ★ 101.65 |
| 52 Week Low | $39.87 | $23.56 |
| 52 Week High | $90.75 | $64.09 |
Technical Indicators
Market Signals| Indicator | PCVX | CELH |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 49.46 |
| Support Level | $52.91 | $27.13 |
| Resistance Level | $62.00 | $30.19 |
| Average True Range (ATR) | 4.10 | 1.10 |
| MACD | -0.68 | 0.15 |
| Stochastic Oscillator | 2.27 | 47.73 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About CELH Celsius Holdings Inc.
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It focuses on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.